Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $264
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Overweight rating on Ascendis Pharma but lowers the price target from $277 to $264.
September 04, 2024 | 1:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo has maintained its Overweight rating on Ascendis Pharma but has reduced the price target from $277 to $264, indicating a slightly less optimistic outlook.
The maintenance of an Overweight rating suggests continued confidence in Ascendis Pharma's potential, but the lowered price target reflects a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100